News

News Subscription

Feb 14. 2023 / Ad hoc announcement
Basilea reports strong financial results 2022 based on successful implementation of new strategy
Read more
Download
Feb 07. 2023
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer
Read more
Download
Jan 24. 2023 / Ad hoc announcement
Basilea reports preliminary operating profit for 2022, significantly above guidance
Read more
Download
Jan 11. 2023 / Ad hoc announcement
Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update
Read more
Download
Jan 09. 2023 / Ad hoc announcement
Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basilea
Read more
Download
Dec 28. 2022
Basilea announces repayment of 2022 convertible bonds
Read more
Download
Dec 23. 2022
Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan
Read more
Download
Dec 19. 2022
Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen
Read more
Download
Nov 02. 2022
Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics
Read more
Download
Oct 24. 2022
ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB)
Read more
Download